|

Cohort 1, GNR-084 Clinical Trials

1 actively recruiting trial

Also known as: Anti-CD19/CD3 antibody

Pipeline

Phase 1/2: 1

Top Sponsors

  • AO GENERIUM1

Indications

  • GNR-0841
  • B-precursor Acute Lymphoblastic Leukemia1
  • All1
  • Cancer1

Other1 trial

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.